MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia
Key facts
- Who runs it
- MicrobiotiX Co., Ltd
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 18 people, planned
- Started
- 25 Jul 2026
- Expected to end
- Dec 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- MP101
- Antibiotics
- Record updated
- 28 July 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Subjects aged 19 years or older
- Clinical diagnosis of acute pneumonia with radiologic evidence of pulmonary infiltrates
- Confirmed Pseudomonas aeruginosa (PA) infection via valid respiratory specimens
- PA isolate demonstrates susceptibility to MP101 and non-susceptibility to current antibiotic therapy
- Adequate organ function as defined by hematological, hepatic, and renal laboratory parameters
Who cannot take part
- Known hypersensitivity to bacteriophages, study components, or concomitant antibiotics
- Participation in another clinical trial within 30 days prior to screening
- Persistent septic shock or hemodynamically unstable condition
- Active pulmonary tuberculosis or non-bacterial pneumonia
- Clinically significant cardiovascular, hepatic, or renal impairment
- Immunocompromised status or hematological malignancies
- Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for the study
- Significant pleural effusion or lung abscess requiring therapeutic drainage
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MP101 administered in addition to standard antibiotic therapy in adult patients with acute Pseudomonas aeruginosa pneumonia. The study will also assess the pharmacokinetic and pharmacodynamic characteristics of MP101 and its antibacterial activity, including changes in P. aeruginosa burden in sputum and changes in susceptibility to MP101 and concomitant antibiotics.
The 3 groups in the trial
- Low-dose cohort (Cohort A)Treatment being tested
Participants in the low-dose cohort (Cohort A) will receive a single intravenous infusion of MP101 in addition to standard antibiotic therapy.
Treatment: MP101 and Antibiotics
- High-dose cohort (Cohort B)Treatment being tested
Participants in the high-dose cohort (Cohort B) will receive a single intravenous infusion of MP101 in addition to standard antibiotic therapy.
Treatment: MP101 and Antibiotics
- Placebo groupPlacebo, for comparison
Participants in the placebo group will receive a single intravenous infusion of placebo in addition to standard antibiotic therapy.
Treatment: Antibiotics
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of MP101 in Adult Patients With Acute Pseudomonas Aeruginosa Pneumonia
- Record updated
- 28 July 2026